Great Lakes Advisors LLC purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,932 shares of the company’s stock, valued at approximately $832,000.
Several other large investors have also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its holdings in Astrana Health by 94.4% in the 1st quarter. Sei Investments Co. now owns 134,899 shares of the company’s stock valued at $3,308,000 after purchasing an additional 65,509 shares in the last quarter. Principal Financial Group Inc. increased its position in Astrana Health by 15.7% during the 1st quarter. Principal Financial Group Inc. now owns 265,948 shares of the company’s stock worth $6,521,000 after purchasing an additional 36,150 shares during the period. Hussman Strategic Advisors Inc. increased its position in Astrana Health by 200.0% during the 4th quarter. Hussman Strategic Advisors Inc. now owns 63,000 shares of the company’s stock worth $1,563,000 after purchasing an additional 42,000 shares during the period. UBS Group AG raised its stake in shares of Astrana Health by 48.4% during the 4th quarter. UBS Group AG now owns 176,100 shares of the company’s stock worth $4,369,000 after buying an additional 57,432 shares in the last quarter. Finally, Louisiana State Employees Retirement System purchased a new position in shares of Astrana Health during the 1st quarter worth approximately $468,000. 52.77% of the stock is owned by hedge funds and other institutional investors.
Astrana Health Price Performance
ASTH stock opened at $39.35 on Friday. The firm has a 50 day moving average of $41.39 and a 200-day moving average of $33.39. Astrana Health, Inc. has a 12-month low of $18.08 and a 12-month high of $51.60. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 1.05. The company has a market cap of $2.19 billion, a price-to-earnings ratio of 47.99 and a beta of 0.87.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Weiss Ratings raised Astrana Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, June 1st. Barclays increased their price objective on Astrana Health from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Robert W. Baird set a $45.00 target price on Astrana Health in a report on Friday, May 8th. TD Cowen raised their target price on Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen lowered shares of Astrana Health from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Astrana Health has an average rating of “Moderate Buy” and an average target price of $49.43.
View Our Latest Research Report on ASTH
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
Featured Articles
- Five stocks we like better than Astrana Health
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
